Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

New research published today in eLife demonstrates a new function for Wiskott-Aldrich Syndrome (WAS) protein in the activation of T cells, which play a central role in our immune system.

The study, led by Professor Michael Dustin of the Kennedy Institute, NDORMS in collaboration with Dr Sudha Kumari at MIT furthers our understanding of the regulation of T cell activation – an essential part of our immune response to different types of diseases – and its dysfunction in WAS patients.

WAS is a rare serious disease affecting between 1 and 10 people in a million worldwide, usually male (90%). People suffering from WAS have abnormal or nonfunctional white blood cells (which are part of the immune system) and are at increased risk of developing several immune and inflammatory disorders. There is also a significant reduction in the size and number of platelets, causing those affected to bleed easily.

The condition is caused by mutations or defects in the WAS gene, responsible for giving the instruction to make the Wiskott-Aldrich Syndrome Protein (WASP).  WASP is known to be able to produce new actin cytoskeleton, a network of fibers that make up the cell's structural framework.  The new research identifies how WASP is involved in passing on signals from the surface of T cells through the actin cytoskeleton to the cells core.

Professor Dustin says: “This was a heroic effort by Dr. Kumari, which required an arsenal of new tools. This effort opens a way forward to much needed new therapeutics for WAS and more common immunological diseases such as allergies.”

Similar stories

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Vascular loss shown to be the primary hallmark of aging

Research

New Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.

Immunology preprint reviews launched in Nature Reviews Immunology

Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

Drug may boost vaccine responses in older adults

General Research

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

Living reviews launched by Oxford and Cardiff in the wake of COVID-19 research

Research

In a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of “living reviews” in Oxford University Press’s new open access journal “Oxford Open Immunology”.

3D imaging reveals the role of blood vessels in hormone production

Research

New research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.